CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the " Company " or " CARMAT "), today provides an update on the renegotiation of the repayment terms of its loans with its financial creditors.